Angela Listì

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

Francesco Passiglia, Giuseppe Bronte, Viviana Bazan et al. · Oncotarget · 2016 · 165 citations · Full text

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

Francesco Passiglia, Antonio Galvano, Marta Castiglia et al. · Therapeutic Advances in Medical Oncology · 2019 · 64 citations · Full text

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus

Daniela Cabibi, Stefano Caruso, Viviana Bazan et al. · Oncotarget · 2016 · 40 citations · Full text

Esophageal Cancer, Immunology, Gastroenterology +16

Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis

Francesco Passiglia, Sérgio Rizzo, Christian Rolfo et al. · Current Cancer Drug Targets · 2018 · 39 citations · Full text

A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design

Francesco Passiglia, Paolo Bironzo, Luisella Righi et al. · Clinical Lung Cancer · 2020 · 29 citations · Full text

Dna Repair Genes, Pd-l1 Expression, Niraparib Plus Dostarlimab +11